This Big Pharma Just Went to the Dogs, and That's Great News for Shareholders

Following a week of vigorous M&A activity, this struggling Big Pharma stands out as perhaps the biggest winner.

Apr 24, 2014 at 12:03PM

I honestly struggle to think of a week as exciting as what we've witnessed over the past few days in terms of merger and acquisition activity (and rumors) within the pharmaceutical sector.

Over the weekend there were rumblings that Pfizer was readying to make a $101 billion bid to acquire U.K. rival AstraZeneca. The informal talks have stopped, but the sheer notion that such a huge merger was even a remote possibility greatly improved investors' appetite for risk.

Then, early Tuesday morning, Novartis announced a sweeping reform and refocusing of its operations via the $14.5 billion acquisition of GlaxoSmithKline's oncology unit, the sale of its vaccine unit to Glaxo for $7.1 billion, and the sale of its animal health division to Eli Lilly (NYSE:LLY) for $5.4 billion.  

Finally, on Tuesday as well, we learned that Valeant Pharmaceuticals had made a hefty bid to acquire Allergan for 0.83 Valeant shares and $48.30 in cash for each share of Allergan. Overall, the deal was worth $46 billion when it was announced. Allergan has since adopted a poison pill to prevent the attempted takeover by Valeant and hedge fund manager Bill Ackman.

Like I said, it was a remarkable week, but it was crucial for one Big Pharma in particular: Eli Lilly.

LabsSource: Eli Lilly.

Eli Lilly's "parade of failure"
In my opinion, Eli Lilly's development pipeline is the weakest among Big Pharma.

The company's experimental Alzheimer's disease therapy solanezumab didn't meet its primary endpoint in a late-stage study in 2012 (although it is being studied further in an investigator-sponsored trial overseas in early onset Alzheimer's). Then, in 2013, enzastaurin missed its primary endpoint in a phase 3 trial for diffuse large B-cell lymphoma; edivoxetine failed to meet its primary endpoint as an add-on therapy for major depressive disorder in a late-stage study; and in September ramucirumab missed its primary endpoint in a breast cancer study. This parade of failure hasn't gone over well with investors who are itching for Eli Lilly to find ways to replace revenue from drugs that are losing patent protection.

The good news is that Lilly may have found the smartest solution imaginable. Instead of purchasing a small or midsized biopharmaceutical for its pipeline, and risking it failing as well, the company invested in one of the most stable and growing sources of cash flow imaginable -- the animal health business.

Not cheap, but a genius move
The purchase price for Novartis' animal health division wasn't cheap at $5.4 billion, or roughly five times last year's sales, but it makes a moat of strategic sense for Eli Lilly.


Source: Ryan Thompson, Wikimedia Commons.

Novartis' animal health division is particularly focused on the commercial market in 40 countries, providing anti-parasitic medication and vaccines for livestock. This isn't to say Lilly's Elanco didn't have this focus already, but it will greatly expand Elanco's presence around the world with regard to vaccines, and give the company a larger commercial presence. The move also better positions Eli Lilly to get its foot in the door in emerging markets that offer a more robust growth rate than the established markets where it conducts the majority of its business.

Combined, the two businesses will be capable of somewhere in the neighborhood of $3.5 billion in sales this year, instantly making Lilly the second-largest global animal health provider behind only Zoetis, which is expected to bring in more than $4.7 billion in revenue this year.

As you might imagine, there are some huge advantages to this combination beyond just the cost synergies which should help boost Eli Lilly's bottom line. Let's look at a few of those benefits.

The benefits of a larger animal health company
To start, larger companies have more pricing leverage. Just as pharmacy-benefit managers negotiate drug prices with Big Pharma, prices for animal health vaccines and medications are determined in similar fashion. This means a larger company can use its clout and market share to its advantage when it comes to pricing therapies high enough to earn a healthy profit.

The second point is that patents and competition within the animal health sector simply aren't comparable to what we see in drugs intended for humans. There are a finite number of truly global animal health players, and few of them really compete with each other on a disease-to-disease basis. This means that even when a patent expires there won't necessarily be a generic version of the drug to take its place. Since branded pharmaceuticals yield better margins than generics, we're talking healthier margins for a longer period of time.

Lastly, as it relates to the companion animal segment, many people have adopted our dogs, cats, and other animals as members of their families. One important aspect of this thinking is that many pet owners are willing to pay whatever is necessary to ensure the health of their "family member," thus giving animal health companies plenty of pricing and demand leverage.

The proof is in the numbers
The growth in pet expenditures is absolutely phenomenal. According to the American Pet Products Association, some 62% of U.S. households currently own a pet, and expenditures have increased from less than $30 billion in 2001 to an estimated $55 billion in 2013. This steady growth of about 5% per year is highly sustainable given the need for livestock as the planet's population grows, and as more pets are adopted into households domestically and around the globe.

Keep in mind this is just one fix for Eli Lilly, and it certainly won't solve the company's mammoth patent cliff issues. However, it's the first major step I've seen the company take in the right direction in I can't even remember how long. While I'm still not sold on Eli Lilly's current valuation, my view of the company has certainly improved following this astute acquisition.

One of the biggest allures of Big Pharma is juicy dividends. If income is what you're after then have a gander at these high-yield dividends chosen by our top analysts
The smartest investors know that dividend stocks simply crush their non-dividend paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.


Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool owns shares of, and recommends Valeant Pharmaceuticals. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers